Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waxman Bill Would Alter OTC Ad Rules, Streamline FDA Monograph Authority

This article was originally published in The Tan Sheet

Executive Summary

Democrats are seeking to significantly increase FDA authority over over-the-counter drug monographs and potentially change the face of OTC advertising, prompted by recent high-profile concerns over pediatric cough/cold medications

You may also be interested in...



Acetaminophen Risk Management On Tap For Joint Advisory Panel

FDA is looking for risk-management solutions to liver problems linked to the misuse of acetaminophen in OTC and prescription products, and will convene a joint advisory panel to discuss potential steps to take

Acetaminophen Risk Management On Tap For Joint Advisory Panel

FDA is looking for risk-management solutions to liver problems linked to the misuse of acetaminophen in OTC and prescription products, and will convene a joint advisory panel to discuss potential steps to take

Acetaminophen Risk Management On Tap For Joint Advisory Panel

FDA is looking for risk-management solutions to liver problems linked to the misuse of acetaminophen in OTC and prescription products, and will convene a joint advisory panel to discuss potential steps to take

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS101098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel